A study from the Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Texas, USA shows that “Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice.” This study was published in the 13 Feb 2012 issue of the journal “Journal of Clinical Investigation.“
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary diabetic cardiomyopathy: IL-1β inhibits the development of diabetic cardiomyopathy via down regulation of its target gene Foxo1.
Significance: It has been shown that cardiovascular disease is the principal cause of death in diabetic patients. This study suggests, for the first time, that IL-1β, by increasing the expression of its target gene, it may decrease the expression of its target gene FoxO1. Thereby, it inhibit the development of diabetic cardiomyopathy. Thus, pharmacological formulations encompassing “IL-1β activators” may be used to diabetic cardiomyopathy.
Undisclosed information: How IL-1β decreases the expression of Foxo1
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Interleukin-based therapy for pulmonary diabetic cardiomyopathy: IL-1β inhibits the development of diabetic cardiomyopathy via down regulation of its target gene Foxo1, 9/May/2015, 12.18 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org